The pathogenesis of bicuspid aortic valve (BAV)-associated aortopathy is poorly understood, and no prognostic biomarker is currently available.
T he current knowledge of bicuspid aortic valve (BAV)-related aortopathy is recognized to be inadequate, 1 especially in its pathogenetic and prognostic aspects. Patients are usually operated on electively, to prevent the risk of acute aortic events, namely aortic rupture and aortic dissection, on the basis of "dimensional" criteria of indication, that is, aortic diameter and size progression rate. 2 However, it is now understood that dimensional criteria alone are not enough to adequately manage BAV aortopathy, inasmuch as a heterogeneous disease, especially in terms of prognosis 3 : thus additional "nondimensional" criteria for risk stratification are needed.
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The search for putative risk markers of BAV aortopathy is particularly lively; however, most studies have addressed imaging-based markers, [4] [5] [6] whereas only few focused on the identification of biochemical markers. [7] [8] [9] Indeed, a biomarker of aortopathy should be of pathogenetic significance, and ideally it should have limited correlation with aortic diameter to provide additional information for prognostic stratification alongside this parameter.
The transforming growth factor-β (TGF-β) network is attracting an increasing attention, by virtue of its role in fibrosis, inflammation, cell proliferation and migration, extracellular matrix (ECM) remodeling, and in light of its involvement in aortopathy syndromes, such as Loeys-Dietz and Marfan syndromes. [10] [11] [12] [13] [14] [15] [16] [17] [18] The molecular targets considered in this study were selected based on their known interplays with the TGF-β network (Figure 1, top) . Endoglin (ENG) is a type 3 TGF-β1 receptor, devoid of kinase activity but able to modulate TGF-β1 binding and signaling by association with 2 TGF-β type I receptors (ALK-1 and ALK-5) 13 : mainly expressed by endothelial cells, it is involved in angiogenesis and redox homeostasis. 13, 14 The extracellular domain of ENG can be cleaved by the membranebound matrix metalloproteinase-14 (MMP-14) and circulate as soluble ENG (sENG), able to sequester circulating TGF-β1, inactivating it. 15 Different signaling pathways (canonical and noncanonical) mediated by TGF-β1 can lead to the activation of either wound-healing/fibrosis transcriptional programs (including the expression of connective tissue growth factor [CTGF]) or to ECM degradation (including the expression of MMP-2). 12 Both TGF-β1 signaling and matrix proteolysis are amplified by reactive oxygen species, 18 whereas extracellular reactive oxygen species scavengers like the superoxide dismutase 3 (SOD3) limit reactive oxygen species activities, thus dismutase activity can indirectly modulate TGF-β1 signaling (Figure 1, top) .
In this study, we assessed whether any of the abovementioned TGF-β1-related molecules, may be an early BAV aortopathy biomarker, either individually or combined. Having found changes in the expression of both TGF-β1 and its receptor ENG, for the first time in literature, we also estimated the ratio of serum TGF-β1 to sENG in patients with BAV and sought for a possible prognostic value for aortopathy development in longitudinal assessment of BAV patients without aorta dilatation at baseline.
Methods
Patients
Aortic wall samples from 167 patients with aortic valve stenosis undergoing surgery, with or without associated aortopathy, and from 32 heart transplant donors ("controls") with negative personal and familial history of BAV or aortopathy were included in this study. The study was approved by the involved institutions' ethics committees and performed in accordance with the Declaration of Helsinki. All patients gave their informed consent before their inclusion. Sixty patients had tricuspid aortic valve (TAV) stenosis with normal or mildly dilated ascending aorta (echocardiography-measured maximal aortic diameter ≤45 mm), 66 had a stenotic congenital BAV (nonfamilial and nonsyndromic) with normal or mildly dilated aorta (≤45 mm, BAV non-dil group) and 41 had BAV stenosis with "ascending phenotype" aortic dilatation (>45 mm, BAV dil group). Clinical characteristics are summarized in Table 1 . We selected only patients with predominant aortic valve stenosis because differences have been previously demonstrated in gene expression and aortic histology between BAV patients with stenosis versus regurgitation. 17 Patients with impaired systolic ventricular function, other cardiac diseases or aortic dissection were excluded. No patient or sample involved in this study had been included in our previous biomolecular investigations. 16 
Aortic Wall Sample Collection
At surgery, 2 samples were retrieved from each ascending aorta (60 TAV, 49 BAV non-dil , and 41 BAV dil ), according to a previously proposed protocol, 16, 17 from the so-called convexity (greater curvature) and the concavity (lesser curvature) regions, respectively, 1 to 2 cm distal to the sinotubular junction (from the ends of the transverse aortotomy 
Novelty and Significance
What Is Known?
• The aortopathy associated with congenital bicuspid aortic valve (BAV) is characterized by heterogeneity of clinical manifestation and course. • Validated tools to stratify patients with BAV according to their individual risk/severity of aortopathy are currently lacking.
• The transforming growth factor-β1 (TGF-β1) pathway has been previously suggested to be pathogenetically involved in BAV aortopathy.
What New Information Does This Article Contribute?
• In patients with BAV undergoing surgery for aortic valve stenosis, a higher ratio of serum TGF-β1 to endoglin (ENG, a TGF-β1 receptor subunit that can be also shed in the serum) was associated with a deleterious gene expression signature in the ascending aorta.
• The TGF-β1/ENG ratio also correlated with the rate of postoperative progression of aortic dilatation over a mean echocardiographic followup time of >3 years.
As aortic diameter seems to be a suboptimal criterion to stratify the risk of aortic events in subjects with BAV, identification of circulating biomarkers might be helpful in BAV aortopathy management. However, a biochemical risk-marker with pathogenetic and prognostic significance has not been identified so far.
In this study, we found that patients with BAV undergoing aortic valve replacement for aortic stenosis have significantly increased serum TGF-β1/ENG ratios when compared with control subjects, with and without generic cardiovascular risk factors. The ratio was higher in BAV patients with aortic dilatation >45 mm. In patients with aortic diameter <45 mm, a higher TGF-β1/ENG ratio was associated with worse gene expression changes in the aortic wall, including increased matrix metalloproteinase-2 and TGF-β1 expression and decreased superoxide dismutase 3 expression. This gene expression profile suggests more severe maladaptive aortic wall remodeling. Moreover, during a 3-year follow-up, patients with higher TGF-β1/ENG ratios at baseline showed faster growth of the ascending aorta in the postoperative period. These results suggest that the TGF-β1/ENG ratio is a useful biomarker that correlates with the rate of progression of aortic dilatation in patients with stenotic BAV, and could have potential value in BAV aortopathy risk stratification.
in patients without dilatation). Samples were immediately stored in RNALater (Qiagen) at −80°C for subsequent RNA extraction or in 4% buffered formaldehyde for subsequent histological and immunohistochemical analysis.
Blood Collection and ELISA
Blood samples for ELISA were obtained preoperatively by venipuncture from all patients with BAV and patients with TAV. Blood samples were also obtained from 11 TAV healthy volunteers in whom the presence of cardiovascular diseases had been previously excluded (control group I, low cardiovascular risk) and from 21 TAV subjects without aortic diseases from a cardiovascular medicine outpatient clinic (control group II, higher cardiovascular risk). Clinical characteristics are summarized in Table 1 . Methods of collection, separation, and assay are detailed in the Online Data Supplement.
Histological Analysis and Immunohistochemistry
Morphological analysis was performed on aortic cross-sections from the aortic convexity and concavity from 6 donor subjects, 6 TAV, and 6 BAV non-dil patients. Besides routine grading of medial degeneration, morphometry of the intimal and medial layers was performed as previously described. 17 The expression and localization of the target protein ENG were analyzed by immunohistochemistry on aortic cross-sections adjacent to those used for histological analysis (Online Data Supplement).
Gene Expression Analysis by Real-Time Reverse Transcription Polymerase Chain Reaction and Western Blotting
Total RNA was extracted from whole aortic samples (22 donors, 50 TAV, 39 BAV non-dil , and 31 BAV dil ) using the RNAeasy minikit (Qiagen). Gene expression analysis was performed as described previously, 16 using semiquantitative reverse transcription polymerase chain reaction (RT-PCR) and real-time RT-PCR with SYBR Green for selected targets (detailed in the Online Data Supplement). Proteins were extracted from whole aortic samples (10 for each group) and Western blot detection of TGF-β1 active dimer, and ENG has been performed as detailed in Online Data Supplement.
Echocardiographic Follow-Up
All patients underwent postoperative echocardiography follow-up every 6 months at our Institution. By the end of the study, the aortic diameters measured by echocardiography in the 39 BAV non-dil patients whose aortic samples had been used for gene expression experiments and who had reached at least 1 year of postoperative follow-up were included in a correlation analysis between the assayed circulating products and the yearly growth rate of their ascending aorta, a currently accepted surrogate parameter for aortopathy severity. This was defined as the difference between the echocardiographic diameter of the aorta (ascending tract at the level of the right pulmonary artery, in mm) at last follow-up visit and the baseline diameter (measured after the operation, before discharge), divided by the length of follow-up (in years). A further group of 17 BAV non-dil patients underwent baseline assay of the TGF-β1/ENG (T/E) ratio and postoperative echocardiographic follow-up of the aortic diameter: the respective data were included in the correlation analysis as well, for prospective validation.
Statistical Analysis
Statistical analysis was performed using the SPSS version 21.0 (IBM) and GraphPad software (Prism 4.0). Variables considered in Figure 1 . The pathways explored and some of the main findings in this study. Top, The pathways in which the molecules targeted by the present study are involved. Transforming growth factor-β1 (TGF-β1) noncanonical signaling leads to expression of matrix metalloproteinase-2 (MMP-2) and the activity of MMP-2 can release TGF-β1 from the extracellular matrix (ECM)-bound latency complex; MMP-14 is involved in the activation of MMP-2 and vice versa; MMP-14 is able to cleave endoglin (ENG) into a transmembrane portion and a soluble circulating portion, soluble ENG (sENG). Bottom, In this study, we show that the ratio of serum TGF-β1 to sENG can be reflective of the gene expression changes that we observed in the aortic tissue (including increased MMP-2 and TGF-β1 expression and decreased MMP-14 and superoxide dismutase 3 [SOD3] expression) of patients with bicuspid aortic valve (BAV). CVX indicates convexity.
the analysis included clinical features (listed in Table 1 ), gene expression data, and serum concentration of target molecules. Differences among groups of subjects were sought for, in terms of all the above variables, by parametric or nonparametric tests for multiple comparisons. Correlations were assessed both between pairs of gene expression data (eg, between MMP-2 gene expression and TGF-β1 gene expression) and between the expression of each gene and the serum concentration of target proteins (eg, between ENG gene expression and sENG level).
Multivariable linear regression analyses were performed, both in the overall study population and in the BAV non-dil subgroup, to identify independent predictors of the ratio of serum T/E ratio, a parameter previously introduced in a different setting. 19 See Online Data Supplement for details.
Results
Clinical features of patients are summarized in Table 1 . As expected, the population with BAV was younger than the TAV cohort, and the 2 control groups differed significantly in terms of hypertension, hypercholesterolemia, and medications.
Gene expression profiles in TAV, BAV non-dil , and BAV dil Patients
Gene expression changes assessed by RT-PCR in this study showed different signatures in the 3 study groups (TAV, BAV non-dil , and BAV dil ). TGF-β1 gene expression increased in BAV non-dil patients at the convexity compared with controls (P=0.04), whereas it was similar to controls in BAV dil patients at the convexity and even decreased at the concavity (Figure 2 ). MMP-2 gene expression was increased at the convexity in both TAV and BAV non-dil patients (Figure 2 ), but not in BAV dil patients. SOD3 gene expression showed opposite trends in patients with TAV versus patients with BAV: it increased at the convexity only in patients with TAV versus controls, whereas it significantly decreased at the concavity in all patients with BAV, with the greatest decrease in BAV dil subgroup (Figure 2) . CTGF gene expression increased in patients versus controls, and in patients with patients it was higher at the concavity than at the convexity (Figure 2 ). MMP-14 gene expression decreased in patients with patients versus controls and TAV, being significantly lower in aortic convexity than in concavity in BAV subgroups (Figure 2 ). ENG gene expression exhibited a significant decrease in all patients versus controls ( Figure 2) . The use of a primer pair that produces 2 distinct PCR products for the L-ENG and the S-ENG alternatively spliced isoforms (Online Table II ) revealed the exclusive expression of the L-ENG isoform (150 bp band) in all aortic samples (data not shown).
When clinical variables were considered (Table 1) , CTGF mRNA expression at convexity and ENG mRNA expression at convexity showed significant correlation with indexed left ventricular mass in BAV non-dil patients (r=−0.71; P=0.01) and in BAV dil patients, respectively (r=0.80; P=0.005). Medications did not affect gene expression in any group.
TGF-β1 and ENG Protein Expression
Western blot analysis confirmed the increased expression of TGF-β1 found at the mRNA level in BAV non-dil patients at the convexity compared with controls; differently from the mRNA level, the expression of the TGF-β1 active dimer was increased compared with controls in BAV dil patients as well (Figure 3 ). ENG expression at protein level matched the corresponding mRNA profile in all patient groups at the convexity, showing a marked decrease compared with controls (Figure 3) , while it remained similar to controls in all patients at the concavity (Figure 3) . Western blot analysis also confirmed a higher expression of ENG in aortic concavity versus convexity in all the patient groups we examined.
The immunohistochemical analysis of ENG revealed its localization in the intima layer of controls ( Figure 4A ), while it was expressed only in a thin periluminal layer of cells in TAV and BAV non-dil aortic samples ( Figure 4B and 4C) . Indeed, the histological analysis revealed a marked alteration of the intima layer in TAV and BAV non-dil patients: while in control subjects the intima was negative to the elastic lamina autofluorescence that characterizes the media, a homogeneous autofluorescence was detectable in aortic samples from patients, without a clear distinction between the intima and the media (data not shown). ENG expression was also detected in sporadic cells in the media of all aortic samples ( Figure 4G through 4I) .
Correlations Between mRNA Expression Levels of Pairs of Target Genes
To gain more insights into the possible coexpression/coregulation of target genes, we analyzed the correlations between pairs of gene expression data in the 3 subgroups of patients (Table 2) . Some correlations were significant in all subgroups, suggesting gene interplays or coregulation irrespective of valve morphology (TAV/BAV) and regardless of the aortopathy status (dil/nondil). Conversely, other significant correlations were specific of a single patient subgroup, including a significant positive correlation between TGF-β1 and CTGF expression at the convexity in patients with TAV (Table 2) , and significant negative correlations of MMP-2 expression with SOD3 and ENG expression at the convexity in BAV dil patients only.
Altered Serum Concentration of TGF-β1 and ENG in Patients With TAV and Patients With BAV
We assessed the serum concentration of the products of the genes under investigation in healthy TAV subjects (control group I, low cardiovascular risk), TAV subjects with cardiovascular comorbidities but without aortic disease (control group II, higher cardiovascular risk) and in TAV stenosis, BAV non-dil and BAV dil patients. The mean serum concentration of the target proteins in subjects with TAV belonging to control groups I and II fell in the basal concentration range, when provided by the manufacturer, or was comparable to published data from healthy subjects (Online Table I ). 20 No significant difference in serum levels of the target proteins was found between control groups I and II ( Figure 5 ).
TGF-β1 serum concentration showed a significant decrease in TAV and in BAV non-dil patients versus healthy subjects. The difference in TGF-β1 serum concentration between BAV non-dil and BAV dil failed to reach a statistical significance ( Figure 5 ). Also sENG concentration showed a marked significant decrease in all 3 subgroups of patients.
We then calculated the serum T/E ratio as already done elsewhere in a different setting 19 : it was significantly increased in all patients with BAV versus healthy subjects and was significantly higher in BAV dil patients versus BAV non-dil patients ( Figure 5 ). MMP-14 was undetectable in almost all the serum samples we analyzed and consequently was not included among the final data. MMP-2, SOD3, and CTGF serum concentration showed no significant change in patients versus healthy subjects ( Figure 5 ).
Medications and clinical variables (Table 1) did not affect the serum concentration of target molecules in any subgroup. 
Correlations Between Serum Concentration of Target Molecules and Gene Expression Data
We analyzed the correlation between gene expression and serum concentration of the target molecules in the 3 patient subgroups. Notably, in BAV non-dil patients, TGF-β1 and MMP-2 gene expression at the convexity showed significant positive correlations with serum concentration of the corresponding proteins (r=0.61, P=0.006 and r=0.49, P=0.04 respectively). MMP-2 gene expression at the convexity also exhibited a significant positive correlation with serum concentration of TGF-β1 (r=0.61, P=0.007) and SOD3 (r=0.55, P=0.02). All the correlations between gene expression at the concavity and serum concentration of target molecules were found to be weak or nonsignificant.
Serum TGF-β/sENG Ratio
The serum T/E ratio showed a significant positive correlation with TGF-β1 (r=0.52, P=0.03) and MMP-2 (r=0.55, P=0.02) gene expression at the convexity in BAV non-dil patients. The serum T/E ratio also showed a significant negative correlation with SOD3 expression at the concavity in BAV non-dil patients (r=−0.57, P=0.01).
On the basis of the different distribution of values for serum T/E ratio in healthy subjects and in BAV dil patients ( Figure 5 ), an arbitrary cut-off value of 9 was identified and BAV non-dil patients were divided into 2 subgroups, with serum T/E ≥9 (n=17) and with serum T/E <9 (n=22), respectively. BAV non-dil patients with serum T/E ≥9 were found to be significantly older (P=0.03) and to have more marked gene expression changes compared with controls, that is, higher TGF-β1 (P=0.013) and MMP-2 (P=0.009) gene expression at the convexity and lower SOD3 gene expression at the concavity (P=0.04), with no significant difference in terms of aortic diameter (36±5 mm versus 38±4 mm, P=0.34) and other clinical variables.
In multivariable linear regression analysis including all patients with BAV (R sq of the model=0.73, F-test=20.9), the serum T/E ratio was predicted by MMP-2 expression at the convexity (standardized β coefficient=0.36, P=0.003) and by aortic dilatation (β for BAV dil =0.45, P=0.001). When considering BAV non-dil patients only, including age as a covariate (R sq =0.84, F-test=17.2), the expression of MMP-2 at the convexity resulted as an independent predictor of T/E ratio, whereas SOD3 gene expression was an independent inversely associated factor. 
Aortic Growth Rate
Discussion
In this study, we sought for potential circulating biomarkers of aortopathy risk in patients with BAV, basing on the pathogenetic insights achieved by gene expression analysis of TGF-β1 and associated key players of vascular remodeling.
Peculiarities of This Study
Few previous studies addressed with different approaches the issue of identifying possible biomarkers of BAV aortopathy. Ikonomidis et al 7 revealed unique profiles of plasma MMPs, tissue inhibitors of MMPs, and microRNAs in TAV versus BAV patients with aortic aneurysm: that study demonstrated the possibility to predict the presence of specific pathogenic subtypes (ie, TAV or BAV) of aneurysm disease using a plasma multianalyte regression strategy. Our purpose was different: we aimed at identifying a biomarker that could be assayed in BAV patients without a frank aneurysm, but being indicative of a propensity to future development of aortopathy. Branchetti et al 8 reported significant correlation between serum levels of the receptor for advanced glycation end-products and its tissue expression: based on the association of high soluble receptor for advanced glycation end-products levels with disrupted elastin and proteoglycan deposition, irrespective of the diameter, they suggested a possible prognostic value of soluble receptor for advanced glycation end-products measurement. None of these previous studies included a prospective follow-up to clinically test the candidate biomarker, like in this study. Considering the phenotypic diversity of patients with BAV and its expected prognostic implications, 2,3 we selected only aortic valve stenosis patients with surgical indication, being aortic stenosis with dilatation of the tubular tract of the ascending aorta the most frequent phenotype assumed by BAV aortopathy. 18, 21, 22 Indeed, we analyzed a small number of patients with BAV regurgitation, outside of this study, and found markedly higher serum TGF-β levels, well out of the range of the patients with BAV stenosis (data not shown). This further supported our choice to pursue the homogeneity of valve function in all study patients.
We retrieved from each aorta 2 samples, respectively from the concavity and convexity regions, known to be subjected to different biomechanical stimuli to distinguish gene expression changes influenced by hemodynamics from those due to constitutive defect. 6, 16, 17, 23 The recent finding by Guzzardi et al 23 was consistent with this study and with our previous studies of the regional differences in ECM composition 17 and smooth muscle cell phenotype 16 between areas exposed to higher (convexity) and lower (concavity) wall shear stress. Experimentally, TGF-β1 overexpression and TGF-β1 release from the ECMbound latency complex are known to be induced by high shear stress.
11,24
Thus, we postulate that the propensity of patients with BAV stenosis to develop ascending dilatation may consist in a constitutive alteration of mechanosensing and mechanotransduction processes in the aortic wall, possibly leading to a rewiring of the TGF-β signaling through noncanonical pathways. In BAV patients with the "root phenotype" dilatation, less frequent and usually associated with either normal aortic valve function or regurgitation, 4,21 the genetic bases could be different, warranting separate analysis in future studies.
Identifying Candidate Biomarkers
We found an increased TGF-β1 mRNA expression in BAV nondil patients' aorta (Figure 2 ), as already reported in an independent cohort of patients with BAV stenosis, 16 and an activation of TGF-β1 at the convexity in both BAV non-dil and BAV dil patients' aorta ( Figure 3 ). The matter may seem controversial, as other authors, exploring the canonical Smad-mediated pathway, have shown no activation of TGF-β signaling in patients with BAV. 25, 26 However, in murine models of aortopathy, a rewiring of TGF-β signal through the noncanonical pathways was documented. 27, 28 Thus, the 2 pieces of evidence of increased TGF-β1 gene expression/activation 16 and lack of Smad-mediated pathway activation 26 are not necessarily contrasting, as the non-Smad-mediated pathways, known to lead to ECM degradation, 11, 12 may play a role in early BAV aortopathy as well. This hypothesis deserves further investigations.
In a recent report, 28 TGF-β1 serum concentration in patients without genetic syndromes was slightly lower than normal, in agreement with our comparison of patients with nonsyndromic BAV versus healthy subjects ( Figure 5) . The observation that different control subjects without aortic valve disease and respectively with low and higher cardiovascular risk exhibit comparable serum concentrations of study molecular targets (Figure 4) , indicates that the circulating levels of these proteins are not significantly affected by common cardiovascular risk factors ( Table 1 ), and that changes in TAV/ BAV stenosis patients included in this study are specifically related to their valvulo-aortopathy.
In this study, serum TGF-β1 showed a good correlation with the tissue expression of both MMP-2 and TGF-β1 in BAV non-dil patients. However, although serum TGF-β1 was significantly decreased in this group, it was similar to normal in BAV dil patients ( Figure 5 ). Thus, without the "normalization" for sENG (see next paragraph), serum TGF-β1 alone seemed not to be a good candidate biomarker of BAV aortopathy, at least in this series.
To our knowledge, we are the first to report a decreased expression of ENG in patients with BAV, both at mRNA and at protein level (Figures 2 through 4) . Notably, a similar decrease was observed in patients with TAV; therefore, it could be a common feature of aortic stenosis. L-ENG is involved in redox balance, through the regulation of endothelial nitric oxide synthase expression and function. 12, 13 Together, the finding of a decreased expression of ENG in all patients with aortic stenosis and the BAV-specific lack of SOD3 increased expression may suggest a more altered redox balance in patients with BAV than in patients with TAV. Immunohistochemical analysis showed that the decreased expression of ENG was likely related to the marked alteration of the intima layer (Figure 4) , compatible with its thinning or "medialization" and consistent with previous observations in BAV aortas. 16, 30 Until recently, the attention of studies on bicuspid aortopathy was focused on medial cell changes only 10, 12, 31 ; however, the endothelium has been revealed to undergo important phenotypic and functional alterations as well. 32, 33 ENG per se was not taken into consideration as a possible biomarker in this study because there was no linear correlation between circulating sENG and expression levels of ENG in the aorta, possibly because of its posttranscriptional mechanisms of regulation and to the complex interaction with the many functions of MMP-14.
11,15
Tzemos et al 34 previously reported higher MMP-2 serum concentration in BAV patients with aortopathy than in BAV patients without aortopathy (defined by aortic Figure 6 . Correlation between aortic growth rate and serum TGF-β1/endoglin ratio in BAV non-dil patients (filled circles: patients also included in the gene expression analysis; empty circles: patients from the prospective validation subgroup). BAV indicates bicuspid aortic valve.
diameter >40 mm and <35 mm respectively). Using a different size range (≤45 mm versus >45 mm) and selecting only patients with BAV stenosis, we failed to find significant differences in MMP-2 serum concentration between these BAV subgroups ( Figure 5) ; consequently, we did not focus on MMP-2 as a biomarker, notwithstanding the significant correlation between serum concentration and gene expression in the aorta.
CTGF gene expression in patients with BAV was increased (Figure 2 ), but not proportional to the expression of TGF-β1, as in patients with TAV. As a matter of fact, CTGF overexpression may be induced by mechanical cues or by reactive oxygen species, independently from TGF-β1. 31 As serum concentration of CTGF was not statistically different between patients and reference healthy subjects ( Figure 5 ), and showed a wide intragroup variability, we discarded it as potential biomarker. The same applies to serum SOD3.
The Serum T/E Ratio
The serum T/E ratio was previously introduced in different clinical settings and with different aims. 19 To the best of our knowledge, this is the first time that the potentiality of the T/E ratio as an early biomarker of aortopathy in patients with BAV is assessed. The T/E ratio proved independently associated with MMP-2 gene overexpression and SOD3 gene underexpression, uniquely in BAV non-dil patients and significantly correlated with the aortic growth rate in the postoperative follow-up ( Figure 6 ).
Compared with the measurement of serum TGF-β1 only, the assessment of the T/E ratio seems to have an additional value, probably because decreased sENG concentration in BAV non-dil patients may be pathogenetically linked (although not statistically correlated) to the underexpression of the MMP-14 and ENG genes in the aorta. In particular MMP-14 gene expression, consistently with previously reported results at protein level, 35 was significantly lower in BAV dil than in BAV non-dil patients and, consistently, sENG, whose shedding is mediated by MMP-14, showed the same pattern. Thus, the T/E ratio might be a more comprehensive index of the BAVspecific pathogenetically relevant gene expression changes, compared with serum TGF-β1 alone (Figures 1 and 5 ).
Study Limitations
This was a preliminary, unprecedented investigation of a novel aspect of BAV aortopathy. Of course, we have limitations to mention. First, the number of patients with BAV was relatively small, preventing so far a separate analysis of the 2 different BAV morphotypes (Table 1) , and the lack of a TAV dil group. Second, the hypotheses issued on alterations of TGF-β signaling, although consistent with data from the literature, 11, 27, 30, 31, 35 should be experimentally confirmed, eg, in vitro. However, in vitro studies imply other limitations, as they disregard both the tissue context and the hemodynamic influences. Third, RT-PCR and Western blot analysis have been performed on different sets of patients because of the technical limitations related to the small size of samples from nondilated aortas.
Fourth, understanding whether the observed changes in circulating levels of TGF-β1 and sENG may be a cause or a consequence of the expression changes of their respective genes in the patients' aorta went beyond the purpose of this study and warrant further investigation. Finally, although a whole portfolio of MMPs acts in the phenomena of vascular remodeling, 35 we only addressed serum MMP-2 in this study (being serum MMP-14 undetectable in most of the study subjects): others have already tested a larger number of circulating MMPs in patients with BAV 7, 9 and, in the most recent study, with a similar patient phenotype selection as ours, 9 only MMP-2 was consistently associated with aortic dilatation.
The main results of this study, that is, the association of high serum T/E ratio with a deleterious pattern of gene expression in the aorta of BAV non-dil patients, and with a faster progression of aortic dilatation, stand irrespective of the above still unverified hypotheses and other study limitations.
Conclusions
This study showed that a high serum T/E ratio in BAV non-dil patients is reflective of an unfavorable TGF-β1-related gene expression profile in the ascending aorta and is associated with a faster growth rate of the aorta over time, a surrogate index for severity of the aortopathy. Therefore, the serum T/E ratio applies as a candidate biomarker of BAV aortopathy that could possibly indicate closer clinical surveillance or earlier surgical treatment, to be validated in future prospective studies.
